China Reform Health Management and Services Group Co., Ltd. (SHE:000503)
6.99
+0.08 (1.16%)
Aug 28, 2026, 3:04 PM CST
SHE:000503 Revenue
China Reform Health Management and Services Group had revenue of 51.02M CNY in the quarter ending June 30, 2026, with 13.23% growth. This brings the company's revenue in the last twelve months to 356.46M, up 13.15% year-over-year. In the year 2025, China Reform Health Management and Services Group had annual revenue of 350.44M, down -1.81%.
Revenue (ttm)
356.46M
Revenue Growth
+13.15%
P/S Ratio
19.20
Revenue / Employee
286.54K
Employees
1,244
Market Cap
6.84B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 350.44M | -6.45M | -1.81% |
| Dec 31, 2024 | 356.90M | 26.77M | 8.11% |
| Dec 31, 2023 | 330.13M | 19.05M | 6.12% |
| Jan 1, 2023 | 311.08M | 58.56M | 23.19% |
| Jan 1, 2022 | 252.52M | 45.14M | 21.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| WuXi AppTec | 51.52B |
| Shenzhen Mindray Bio-Medical Electronics | 34.29B |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 31.32B |
| Zhonghong Pulin Medical Products | 2.61B |
| Sichuan Biokin Pharmaceutical | 2.54B |
| Edan Instruments | 2.11B |
| GuangYuYuan Chinese Herbal Medicine | 1.41B |
| Beijing Strong Biotechnologies,Inc. | 1.37B |